TMC Innovation Welcomes Startups to 19th HealthTech Accelerator Cohort

Houston, TX (October 28, 2025) – Texas Medical Center Innovation (TMCi) today announced its 2025 HealthTech Accelerator cohort, welcoming 11 medtech startups that combine biomedical engineering, AI, and clinical solutions. This signature program brings entrepreneurs from around the world to the TMC Innovation Factory, connecting them with researchers, top-tier hospital experts, and seasoned advisors to address unmet clinical needs.

“This cohort of startups is tackling some of today’s most pressing clinical challenges, from surgery and respiratory care to diagnostics and women’s health. At TMC, we bring together the minds behind innovation—entrepreneurs, technology leaders, and strategic partners—to help emerging companies validate, scale, and deliver solutions that make a real difference for patients here and around the world. We look forward to seeing their progress and global impact through the HealthTech Accelerator and the support of our broader ecosystem,” said Tom Luby, chief innovation officer at Texas Medical Center.

The HealthTech Accelerator is a six-month program that supports entrepreneurs in further developing their companies by bringing industry leaders to hone participants’ approaches to clinical trials, regulatory strategy, data security, hospital procurement, intellectual property, fundraising, marketing, and other critical areas.

“Every year, we see new innovations that have the potential to transform how people experience healthcare. At TMC, we provide unparalleled expertise in clinical validation and commercialization strategy. This support helps startups refine and validate their technologies before bringing them to market, and ultimately to patients,” said Devin Dunn, director of innovation accelerators at Texas Medical Center.

The chosen cohort of participants starts the program on November 3, 2025, for an inaugural session dedicated to preliminary customer discovery and clinical validation. Then, they will spend five months in the incubator, where founders will benefit from working closely with TMC specialists to refine their go to market plan.

The selected companies and their specialties include:

• OsseoLabs: develops AI-assisted, 3D-printed patient-specific implants for craniofacial and orthopedic surgeries. Their technology enables precise implant design for reconstructive and trauma surgery, advancing personalized care and improving osseointegration.
• Roam Technologies: pioneers tankless oxygen generation devices for chronic respiratory care. Its core innovation, a portable oxygen therapy system (JUNO), provides real-time oxygen delivery optimization for patients with chronic conditions such as chronic obstructive pulmonary disease (COPD).
• SageSpectra: designs an innovative patch system for real-time, remote monitoring of temperature and StO2 for assessing vascular occlusion, infection, and other surgical flap complications.
• OptiLung: develops 3D-printed extracorporeal blood oxygenation devices designed to optimize blood flow, reduce complications, and improve patient outcomes.
• Dozee: created a smart remote patient monitor platform that uses under-the-mattress bed sensors to capture vital signs through continuous monitoring. Its advanced early warning system helps clinicians detect patient deterioration early, without physical contact or manual checks.
• Dynamic Light: developed a non-invasive imaging technology that enables surgeons to visualize blood flow in real-time. By eliminating the need for traditional dyes and offering continuous, high-resolution insights, this technology improves patient outcomes and reduces surgical risks across neurovascular, robotic, and plastic surgeries, among others.
• Endomedix: develops biosurgical devices using its versatile PLEXimine™ platform. Its lead product, PlexiClot™, is a fast-acting absorbable hemostat designed to eliminate the risk of paralysis and reoperation due to device swelling, a common problem in all current absorbable hemostats.
• Xander Medical: focuses on biomechanical innovations that address unmet needs in orthopedic systems and surgical instrumentation. The company’s design addresses the complications and cost burdens associated with the current methods of removing stripped and broken surgical screws.
• Freyya: develops the first on-the-go pelvic floor monitoring and feedback device for people with pelvic floor dysfunction. Their device leverages a tampon-like biosensor to monitor pelvic floor physical therapy.
• Scinvivo: develops optical imaging catheters for bladder cancer diagnostics, improving minimally invasive imaging and real-time visualization during urological procedures.
• Respiree: created an all-in-one cardiopulmonary platform with wearable sensors for respiratory monitoring, using AI to track breathing patterns and detect early signs of distress. Designed for both hospital and home care management of chronic illnesses.

###

About Texas Medical Center (TMC): TMC, the world’s most comprehensive life science ecosystem, is at the forefront of advancing life sciences. TMC is on a mission to further accelerate the pace of healing by harnessing our collective expertise in innovation, research, development, production, and patient care within a single, centralized medical ecosystem. With over 70+ million square feet and 120,000+ employees, TMC is leveraging the collective power by pioneering a revolutionary life sciences initiative to house the entire treatment of life cycle from discovery to delivery, within a single, world-class medical complex, on a scale never before seen.

About Texas Medical Center Innovation: Texas Medical Center Innovation forms, fosters and recruits companies that are writing the future of healthcare. Functioning as an ecosystem to accelerate the development, scaling and commercialization of healthcare and life-science startups, TMCi performs diligence on the companies seeking to progress toward clinical and business milestones in collaboration with Texas Medical Center member institutions and our global network of advisors. We align these resources through our globally recognized programs: Biodesign, Accelerator for Cancer Therapeutics, and Health Tech, which utilize rapid prototyping labs, wet labs and collaborative spaces from the TMC Innovation Factory (former Nabisco building) for medical device creation, bioprinting, and advanced R&D.